POPULARITY
The House Budget Committee moves forward a tax bill with significant cuts to Medicaid. Pennsylvania's governor calls for more oversight of private equity healthcare deals following the closure of Crozer Health. And, Regeneron Pharmaceuticals buys 23andme's assets for $256 million. Those stories and more coming up on today's episode of the Gist Healthcare podcast. Hosted on Acast. See acast.com/privacy for more information.
Microsoft Build and Google I/O, each company's annual developer conference, are taking place this week. As with most AI news these days, we can't cover everything they announced, nor would we want to. But what does this runaway train of AI progress mean for you? Watch on YouTube! - Notnerd.com and Notpicks.com INTRO (00:00) File your Siri lawsuit claim (04:05) Fortnite returns to the App Store for iPhone and iPad (06:05) MAIN TOPIC: Microsoft Build and Google I/O (12:10) Microsoft Build 2025: news and announcements from the developer conference Everything Google announced at I/O 2025: Gemini, Search, Android, and more DAVE'S PRO-TIP OF THE WEEK: Safari remove distracting items (36:25) JUST THE HEADLINES: (44:40) The top fell off Australia's first orbital-class rocket, delaying its launch HBO Max lives! Max to change its name back after 2 years CERN gears up to ship antimatter across Europe Chinese ‘kill switches' found hidden in US solar farms NASA engineers fixed some thrusters on Voyager 1 from 15 billion miles away Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million InventWood is about to mass-produce wood that's stronger than steel TAKES: Airbnb introduces services (46:45) Top tier Adobe Creative Cloud plan increasing to $800 per year (49:35) Microsoft extends Office app support on Windows 10 to 2028 (53:15) KrebsOnSecurity Hit With Near-Record 6.3 Tbps DDoS (54:35) BONUS ODD TAKE: 10,000 Drum Machines (57:05) PICKS OF THE WEEK: Dave: Zhiyun Molus x100 RGB Cam Mackey (01:00:55) Nate: SMALLRIG Camera Cage for Sony ZV-1 II/ZV-1F / ZV-1 Camera, with Silicone Gel Grip, Cold Shoe Mount (01:06:15) RAMAZON PURCHASE - Giveaway! (1:08:30)
The House Budget Committee advanced President Trump's multi trillion-dollar domestic policy package Sunday night, just two days after conservatives voted to reject it. CNBC's Eamon Javers reports on this and President Trump's clash with Walmart over tariff-driven price hikes. Walter Isaacson, biographer and Tulane professor, discusses gene editing breakthroughs and biotech innovation amid federal funding cuts, as well as the White House's relationship with corporate America's leaders. Then, Business Roundtable CEO Josh Bolten weighs in on how CEOs are responding to Trump-era policies, including the President's trade agenda. Plus, Regeneron Pharmaceuticals has announced plans to acquire most of 23andMe's assets for $256 million. Walter Issacson 18:22Josh Bolten 28:39 In this episode:Eamon Javers, @EamonJaversWalter Isaacson, @WalterIsaacsonBecky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinZach Vallese, @zachvallese
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über zwei gelungene Börsengänge, einen weiteren Tiefschlag für Bayer und einen Absturz bei Tui. Außerdem geht es um Etoro, Pfisterer Holding, Super Micro, AMD, Nvidia, Coreweave, Cisco, Eon, Daimler Truck, Brenntag, Renk, Hapag Lloyd, Baidu, WeRide, Uber, General Motors, Mercedes-Benz, BMW, Volkswagen, Pony.AI, Momenta Technology, Tesla, Alphabet, Archer Aviation, Marvell Technology, Broadcom, The Trade Desk, Datadog, MongoDB, Adobe, Diamondback Energy, Regeneron Pharmaceuticals, Warner Bros Discovery, Rheinmetall, Siemens Energy. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Bayer has announced a restructuring that will result in 2,000 job cuts and a reduction in management layers. CEO Bill Anderson believes Trump's most favored nations policy could provide an opportunity for European countries to contribute more to biopharma innovation. Galapagos has abandoned plans for a spinout and cell therapy, causing a stir in the industry. Trump's most favored nation policy has led to a sell-off of PBMs, but analysts believe it may not have a significant impact without further congressional action. Sino Biological offers solutions for autoimmune diseases, with reagents for nearly 50 different conditions. In other news, CMS is preparing for a new cycle of drug negotiations, Azafaros has raised $150 million for rare neuro-metabolic diseases, and Roche's Genentech is investing $700 million in a North Carolina plant. 10x Genomics has cut 8% of its workforce, and there are upcoming webinars on biotech downturns and AI in life science R&D. Job opportunities include positions at 4D Molecular Therapeutics, Takeda, and Regeneron Pharmaceuticals.
Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care. Uncover: · The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? · Mucus plugging and airflow obstruction: What does the latest research reveal? · Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? · The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: · This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. · The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program · The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits · See full US Prescribing Information for dupilumab · MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: · MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. · NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1. Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.
Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care. Uncover: · The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? · Mucus plugging and airflow obstruction: What does the latest research reveal? · Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? · The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: · This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. · The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program · The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits · See full US Prescribing Information for dupilumab · MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: · MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. · NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1. Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.
The researchers say that the one-time therapy gives a working copy of that gene to the inner ear during a medical operation. Most of the children were treated in one ear, although one child in the two-person study was treated in both ears.研究人员说,一次性疗法在医疗操作过程中将该基因的工作副本赋予了内耳。 尽管两人的研究中的一个孩子在两个耳朵中都接受了治疗,但大多数孩子都被一只耳朵接受治疗。The study with six children took place at Fudan University in Shanghai. Dr. Yilai Shu helped lead the study and trained in Chen's laboratory. Chen was involved in the research. Chinese science organizations and biotechnology company Shanghai Refreshgene Therapeutics helped provide financial support. 与六个孩子的研究在上海的福丹大学进行。 Yilai Shu博士帮助领导了这项研究,并接受了Chen的实验室的培训。 陈参与了研究。 中国科学组织和生物技术公司上海刷新的治疗学有助于提供财务支持。Researchers observed the children for about six months. They do not know why the treatment did not work in one of them. But the five others, who were completely deaf, can now hear a normal discussion, the researchers said. 研究人员观察到孩子大约六个月。 他们不知道为什么治疗在其中一种中没有起作用。 研究人员说,但是五个完全聋哑的五个人现在可以听到正常的讨论。 Chen estimated they now hear at a level 60 percent to 70 percent of normal. The therapy caused no major side effects. 陈估计他们现在听到的是正常水平的60%至70%。 该疗法没有引起重大副作用。Early results from other research have shown similar results. 其他研究的早期结果显示出相似的结果。Regeneron Pharmaceuticals is a biotech company based in New York state. It announced in October that a child under two years old showed improvements six weeks after gene therapy. The results came from a study Regeneron did with support from Decibel Therapeutics, a company in Boston. Regeneron Pharmaceuticals是一家位于纽约州的生物技术公司。 它在十月份宣布,两岁以下的儿童在基因治疗六周后表现出改善。 结果来自Regeneron在波士顿公司的Decibel Therapeutics的支持下进行的研究。 Columbia University's Dr. Lawrence Lustig is involved in the Regeneron study. He said although the children in these studies do not end up with very good hearing, “even a moderate hearing loss recovery in these kids is pretty astounding.” 哥伦比亚大学的劳伦斯·卢斯蒂格(Lawrence Lustig)博士参与了Regeneron研究。 他说,尽管这些研究中的孩子们并没有听到很好的听力,但“即使这些孩子的听力损失恢复也令人震惊。” He added that many questions remain. They include how long the therapies will last and if hearing will continue to improve in the children. 他补充说,仍然存在许多问题。 它们包括疗法将持续多长时间,以及儿童的听力是否会继续改善。 Some people question if gene therapy for deafness is ethical. 有些人质疑基因疗法是否对耳聋是道德的。 Teresa Blankmeyer Burke is a professor who is deaf and who deals with medical ethics. She teaches at Gallaudet University, a university for deaf people in Washington, D.C. She said that there is no agreement about the need for gene therapy targeting deafness. Teresa Blankmeyer Burke是一位聋哑人,涉及医学道德的教授。 她在华盛顿特区的聋人大学加洛德大学(Gallaudet University)教授。 She also pointed out that deafness does not cause severe or deadly illness. Blankmeyer Burke said that it is important to work with deaf community members about the importance of gene therapy. She added gene therapy is seen by many as a possible threat to “signing Deaf communities.” 她还指出,耳聋不会引起严重或致命的疾病。 布兰克迈尔·伯克(Blankmeyer Burke)说,与聋人社区成员合作有关基因疗法的重要性很重要。 她补充说,许多人认为基因疗法可能是对“签署聋人社区”的可能威胁。 However, Chen said: “This is real proof showing gene therapy is working.” And he added, “It opens up the whole field.” 但是,陈说:“这是表明基因疗法正在起作用的真正证据。” 他补充说:“这打开了整个领域。”
Comment on the Show by Sending Mark a Text Message.This episode is part of my initiative to provide access to important court decisions impacting employees in an easy to understand conversational format using AI. The speakers in the episode are AI generated and frankly sound great to listen to. Enjoy!The battlefield of workplace accommodations and family caregiving responsibilities takes center stage in our detailed examination of Kemp v. Regeneron Pharmaceuticals. This landmark case illuminates the critical distinction between denying leave and subtly discouraging employees from exercising their rights under the Family and Medical Leave Act.We trace the journey of Denise Kemp, a decade-long employee with a history of promotions and positive performance, whose relationship with her employer deteriorated after seeking flexibility to care for her disabled daughter. The tension between remote work policies and leave rights creates a fascinating legal puzzle that ultimately hinged on technicalities rather than merits.The Second Circuit's ruling provides crucial clarity on what constitutes FMLA interference, establishing that employers can violate the law without ever formally denying leave requests. Yet despite this employee-friendly interpretation, procedural rules—particularly the unforgiving statute of limitations—proved decisive. We explore how timing can make or break employment claims regardless of their underlying validity.Beyond the technical legal analysis, we extract practical lessons for both sides of the employment relationship. For workers, understanding deadlines and documenting problematic interactions becomes paramount. For companies, the case serves as a warning that compliance means more than simply processing paperwork—it requires creating an environment where employees feel genuinely free to exercise their rights without subtle punishment.Have you encountered challenges balancing family care responsibilities with workplace expectations? The evolving legal landscape around remote work accommodations continues to shape both employee rights and employer obligations. Share your experiences or questions about navigating these complex waters. If you enjoyed this episode of the Employee Survival Guide please like us on Facebook, Twitter and LinkedIn. We would really appreciate if you could leave a review of this podcast on your favorite podcast player such as Apple Podcasts. Leaving a review will inform other listeners you found the content on this podcast is important in the area of employment law in the United States. For more information, please contact our employment attorneys at Carey & Associates, P.C. at 203-255-4150, www.capclaw.com.Disclaimer: For educational use only, not intended to be legal advice.
Host: Nathan Falk, MD, MBA, FAAFP Guest: Megan Conroy, MD, MA(Ed), FCCP Patients with chronic obstructive pulmonary disease (COPD) often experience significant delays in diagnosis and treatment due to systemic gaps in management. A recent survey of 400 primary care and pulmonary clinicians uncovered patterns of fragmented care among both specialties. Join Dr. Nate Falk and Dr. Megan Conroy as they dive into the findings and explain how CHEST's COPD Toolkit can help clinicians address these gaps and provide a coordinated approach to COPD management. Dr. Falk is a board-certified family physician as well as a Professor and Founding Residency Director for Family Medicine at Florida State University in partnership with BayCare Health System. Dr. Conroy is a Chair and Assistant Professor in the Division of Pulmonary, Critical Care, and Sleep Medicine at The Ohio State University. This program is produced in partnership with the American College of CHEST Physicians and is supported by Regeneron Pharmaceuticals, Inc.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026.Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026.Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353 – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. A lawsuit against Merck related to the HPV vaccine Gardasil, led by Robert F. Kennedy Jr., has been suspended after confirmation. Biopharma bankruptcies are at a peak, with 14 companies filing for chapter 11 protection in 2023 and numbers remaining high in 2024. Gilead has passed on an option for a cancer drug from Arcus, and Merck has partnered with Epitopea to identify unknown tumor antigens. The American Biomanufacturing Summit is set to take place in April 2025 in San Francisco, bringing together industry leaders for exclusive sessions and networking opportunities. The pharmaceutical industry is facing challenges such as patent cliffs and regulatory changes, with companies like Exelixis looking to next-generation cancer drugs for growth. Novo is seeking $830 million in a fraud case against a Singaporean biotech company over a kidney drug. Additionally, there are insights on site survival for clinical research sites and how biotechs can avoid state and local tax surprises. Trump's administration is reportedly seeking to dismantle parts of the FDA workforce, leading to concerns about job security within the agency.Biopharma bankruptcies remained high in 2024, with 14 companies filing for chapter 11 protection, the most in over a decade. Cour Pharmaceuticals solidified its mission last year with a series a raise. Some biotechs are facing unexpected tax consequences when dealing with big pharma. Several top pharma companies are facing massive patent cliffs, including Merck's Keytruda. Novo seeks $830 million in a fraud case against a Singaporean biotech, while Exelixis looks to next-gen cancer drugs. Biogen and Stoke strike a co-development deal for Dravet syndrome. The FDA faces uncertainty as the Trump team seeks to dismantle the workforce. Aardvark Therapeutics raises $94 million for obesity treatments. Abbott, Life Edit Therapeutics, and Regeneron Pharmaceuticals are hiring for various positions.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Bristol Myers Squibb is seeking to broaden the use of its CAR T cell therapy, Breyanzi, to address marginal zone lymphoma as a strategy to offset losses from exclusivity. In other news, Boehringer Ingelheim has seen promising results in a Phase III trial for its lung fibrosis drug, randomilast, aimed at progressive pulmonary fibrosis. However, Pliant has experienced a stock decline following the halt of its Phase IIb/III study for idiopathic pulmonary fibrosis. Additionally, Vertex has received FDA approval for its non-opioid pain treatment, while AbbVie has secured approval for a new antibiotic. Bain's acquisition of Tanabe for $3.3 billion is also making headlines. Regeneron is currently in a legal battle with Sanofi over the Dupixent pact, and Equillium's itolizumab is undergoing testing against Humira for ulcerative colitis. On the horizon, Acelyrin and Alumis are joining forces to address immune-mediated diseases, while Eisai is seeking subq approval for Leqembi due to sluggish US sales. Job opportunities are available at ATCC, AbbVie, Regeneron Pharmaceuticals, and Dren Bio.
Oral Arguments for the Court of Appeals for the Federal Circuit
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
Oral Arguments for the Court of Appeals for the Federal Circuit
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
Oral Arguments for the Court of Appeals for the Federal Circuit
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/recognizing-atopic-dermatitis-and-prurigo-nodularis-9891SummaryIn this concise CME/CE podcast, a dermatologist and a primary care clinician discuss atopic dermatitis and prurigo nodularis—two conditions that often present with relentless itch and can significantly affect patients' quality of life. Listen as the two clinicians detail the influence of type 2 inflammation and inflammatory cytokines on the pathophysiology of these diseases, as well as describe their clinical manifestations across skin types. By the end of this podcast episode, listeners will feel much more confident in their ability to identify atopic dermatitis and prurigo nodularis in clinical practice.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Recognize the similarities and differences in the clinical presentations, symptoms, and triggers of AD and PN, including in patients with skin of colorDescribe the role of type 2 inflammation in the pathophysiology of AD and PNThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/collaborative-care-in-atopic-dermatitis-and-prurigo-nodularis-9892SummaryIn this concise CME/CE podcast, a dermatologist and primary care clinician review treatment options for patients with atopic dermatitis and prurigo nodularis. Using case examples, the clinicians provide education on individualizing treatment by evaluating patients for treatment progress, modifying treatment plans, and using shared decision-making.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Develop a treatment plan for managing patients with AD and/or PN based on current guidelines and evolving clinical data, including specialty referral when appropriateApply communication strategies to facilitate SDM in the management of patients with AD and PN to improve adherence and outcomesThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MKD865. CME/MOC/AAPA credit will be available until December 19, 2025.Targeting a New Approach in COPD: Understanding the Potential Role of Biologic Therapy in Patients With Evidence of Type 2 Inflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MKD865. CME/MOC/AAPA credit will be available until December 19, 2025.Targeting a New Approach in COPD: Understanding the Potential Role of Biologic Therapy in Patients With Evidence of Type 2 Inflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/MOC information, and to apply for credit, please visit us at PeerView.com/QQD865. CME/EBAC/MOC credit will be available until December 13, 2025.Improving Care for Pediatric and Adult Patients With Eosinophilic Esophagitis: Expert Insights on the Latest Evidence for Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
Oral Arguments for the Court of Appeals for the Federal Circuit
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
Oral Arguments for the Court of Appeals for the Federal Circuit
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/DEA865. CME/MOC/AAPA credit will be available until December 7, 2025.Optimizing Outcomes for Pediatric Patients With EoE: The Importance of Timely Integration of Targeted Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/DEA865. CME/MOC/AAPA credit will be available until December 7, 2025.Optimizing Outcomes for Pediatric Patients With EoE: The Importance of Timely Integration of Targeted Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.